Periodic Reporting for period 1 - DELTA (AI Enabled Managemement of Patients at Risk of Diabetic Foot Ulcer)
Reporting period: 2019-08-01 to 2020-07-31
The objectives of this project are to complete product development of both the hardware and software components of the system, achieve regulatory approvals to market the product, and to commence a series of pilot studies to generate real-world data regarding the product. Alongside these milestones the commercial strategy will be developed. On completion of the project Bluedrop Medical will be in a position to aggressively target the huge market for diabetic foot ulcer prevention and provide real impact to both patients and healthcare systems around the world.
All final testing is due to be completed in the coming months and the results will be used to obtain regulatory approvals.
We have grown our medical advisory board to include influential clinicians and experts in clinical research. This Medical Advisory Board has assisted with the drafting of Instructions For Use documents, pilot study protocols and monitoring protocols.
In addition to product development, regulatory and clinical activities. We have conducted commercial activities involving the expansion of our IP portfolio to new regions and conducting a health economic benefit analysis. We have engaged with further potential distribution partners as well as continuing to work with existing partners.